[
    [
        {
            "time": "2023-10-01",
            "original_text": "Could This Options Trade In AbbVie Generate A 93% Return By September?",
            "features": {
                "keywords": [
                    "options trade",
                    "AbbVie",
                    "93% return"
                ],
                "sentiment_score": 0.75,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "healthcare"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": "neutral"
            },
            "scores": {
                "News_content": "Could This Options Trade In AbbVie Generate A 93% Return By September?",
                "Correlation": 8,
                "Sentiment": 6,
                "Importance": 5,
                "Impact": 7,
                "Duration": 4,
                "Entity_Density": 9,
                "Market_Scope": 3,
                "Time_Proximity": 7,
                "Headline_Structure": 10,
                "Source_Recency": 8
            }
        },
        {
            "time": "2023-10-01",
            "original_text": "AbbVie Seeks FDA Approval for Rinvoq in Ankylosing Spondylitis",
            "features": {
                "keywords": [
                    "FDA approval",
                    "Rinvoq",
                    "Ankylosing Spondylitis"
                ],
                "sentiment_score": 0.8,
                "policy_related": "true",
                "investment_strategy": "false",
                "sector_focus": [
                    "healthcare"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": "neutral"
            },
            "scores": {
                "News_content": "AbbVie Seeks FDA Approval for Rinvoq in Ankylosing Spondylitis",
                "Correlation": 9,
                "Sentiment": 7,
                "Importance": 8,
                "Impact": 8,
                "Duration": 7,
                "Entity_Density": 8,
                "Market_Scope": 4,
                "Time_Proximity": 8,
                "Headline_Structure": 7,
                "Source_Recency": 9
            }
        },
        {
            "time": "2023-10-01",
            "original_text": "Hedge Funds Have Never Been This Bullish On AbbVie (ABBV)",
            "features": {
                "keywords": [
                    "hedge funds",
                    "bullish",
                    "AbbVie"
                ],
                "sentiment_score": 0.9,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "healthcare"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "Hedge Funds Have Never Been This Bullish On AbbVie (ABBV)",
                "Correlation": 9,
                "Sentiment": 8,
                "Importance": 7,
                "Impact": 7,
                "Duration": 6,
                "Entity_Density": 10,
                "Market_Scope": 5,
                "Time_Proximity": 8,
                "Headline_Structure": 8,
                "Source_Recency": 7
            }
        },
        {
            "time": "2023-10-01",
            "original_text": "AbbVie vs Biogen: Which Drugmaker Scores A ‘Strong Buy’ Street Consensus?",
            "features": {
                "keywords": [
                    "AbbVie",
                    "Biogen",
                    "strong buy",
                    "street consensus"
                ],
                "sentiment_score": 0.85,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "healthcare"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "AbbVie vs Biogen: Which Drugmaker Scores A ‘Strong Buy’ Street Consensus?",
                "Correlation": 8,
                "Sentiment": 6,
                "Importance": 6,
                "Impact": 6,
                "Duration": 5,
                "Entity_Density": 7,
                "Market_Scope": 7,
                "Time_Proximity": 7,
                "Headline_Structure": 9,
                "Source_Recency": 6
            }
        }
    ]
]